

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

RECEIVED
CENTRAL FAX CENTER

DEC 18 2006

Amendments to Claims

Kindly amend independent claims 1 and 30 as indicated in the listing of claims below.

Listing of Claims

1. (presently amended) A method for isolating a target population of naturally-occurring post-translationally modified peptides from a complex mixture of peptides, said method comprising the steps of:
 - (a) obtaining a proteinaceous preparation from an organism, wherein said proteinaceous preparation comprises a complex mixture of peptides comprising naturally-occurring post-translationally modified peptides from two or more different proteins;
 - (b) contacting said proteinaceous preparation with at least one immobilized post-translational modification-specific antibody; and
 - (c) isolating said target ~~at least one~~ population of naturally-occurring post-translationally modified peptides specifically bound by said immobilized modification-specific antibody in step (b).
2. (previously presented) The method of claim 1, further comprising the step of (d) characterizing said population of modified peptides isolated in step (c) by mass spectrometry (MS), tandem mass spectrometry (MS-MS), and/or MS³ analysis.
3. (previously presented) The method of claim 2, wherein said mass spectrometry comprises matrix-assisted laser desorption time-of-flight (MALDI-TOF) MS, wherein said tandem mass spectrometry comprises liquid chromatography (LC)-MS/MS, and wherein said MS³ analysis comprises LC-MS³.
4. (previously presented) The method of claims 2 or 3, further comprising the step of (e) utilizing a search program to substantially match the spectra obtained for said modified peptides during the characterization of step (d) with the spectra for a known peptide sequences, thereby identifying the parent protein(s) of said modified peptides.
5. (original) The method of claim 1, wherein said proteinaceous preparation comprises a digested biological sample selected from the group consisting of a digested crude cell extract, a

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

digested tissue sample, a digested serum sample, a digested urine sample, a digested synovial fluid sample, and a digested spinal fluid sample.

6. (original) The method of claim 5, wherein said digested preparation is obtained using at least one proteolytic enzyme or chemical cleavage.

7. (original) The method of claim 6, wherein said proteolytic enzyme is immobilized.

8. (original) The method of claim 6, wherein said proteolytic enzyme is soluble, and wherein said digested preparation is treated with a proteolysis inhibitor prior to said contacting step (b).

9. (original) The method of claim 1, wherein step (a) further comprises pre-purifying said proteinaceous preparation by immobilized metal affinity chromatography (IMAC).

10. (original) The method of claim 1, wherein said immobilized antibody of step (b) is covalently-linked to a chromatography resin or noncovalently-linked to protein-A- or protein-G-agarose.

11. (original) The method of claim 10, wherein said resin is contained within a column or micropipette tip.

12. (original) The method of claim 2, wherein said immobilized antibody of step (b) is immobilized in chromatography resin within a column, said column being coupled to a mass spectrometer for said characterization of step (d).

13. (original) The method of claim 1, wherein said modification comprises phosphorylation.

14. (original) The method of claim 1, wherein said modified peptide(s) comprise(s) a phosphopeptide.

15. (previously presented) The method of claim 1, wherein said post-translational modification-specific antibody comprises a motif-specific, context-independent antibody that specifically binds a motif comprising at least one phosphorylated amino acid.

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

16. (original) The method of claim 15, wherein said motif consists of a single phosphorylated amino acid.
17. (previously presented) The method of claim 15, wherein said motif consists of all or part of a kinase consensus substrate motif or a protein-protein binding motif.
18. (previously presented) The method of claim 17, wherein said kinase consensus substrate motif is selected from the group consisting of mitogen-activated protein kinase (MAPK) consensus substrate motifs, cyclin-dependent kinase (CDK) consensus substrate motifs, protein kinase A (PKA) consensus substrate motifs, AKT consensus substrate motifs, protein kinase C (PKC) consensus substrate motifs, phosphothreonine-X-arginine, and ATM (ataxia telangiectasia mutated) consensus substrate motifs, and wherein said protein-protein binding is a 14-3-3 binding motif or a 3-phosphoinositide-dependent kinase 1 (PDK1) docking motif.
19. (previously presented) The method of claim 1, wherein said post-translational modification-specific antibody is a monoclonal antibody or a polyclonal antibody.
20. (previously presented) The method of claim 1, wherein at least one modified peptide isolated in step (c) corresponds to a known marker of disease.
21. (previously presented) The method of claim 4, wherein at least one modified peptide characterized in step (d) comprises an unknown post-translational modification site of said parent protein.
22. (previously presented) The method of claims 2 or 3, further comprising the step of (e) comparing the modification state of at least one modified peptide characterized in step (d) with the modification state of a corresponding peptide in a reference sample, thereby to compare protein activation in said proteinaceous preparation with protein activation in said reference sample.
23. (original) The method of claim 22, wherein said proteinaceous preparation corresponds to a diseased organism and said reference sample corresponds to a normal organism, whereby comparison of protein activation provides information on activation changes resulting from said disease.

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

24. (original) The method of claim 22, wherein said proteinaceous preparation is obtained from a tissue biopsy cell or a clinical fluid sample and said reference sample corresponds to a diseased organism, whereby the comparison of protein activation provides information useful for diagnosis of said disease.

25. (original) The method of claim 22, wherein said protein preparation corresponds with an organism or preparation treated with at least one test compound and said reference sample corresponds with an untreated organism or preparation, whereby the comparison of protein activation provides information on activation changes resulting from treatment with said test compound.

26. (previously presented) The method of claim 23, wherein the comparison of protein activation identifies at least one modified peptide characterized in step (d) as corresponding to a parent protein not previously reported as so modified in said disease.

27. (original) The method of claim 24 or 25, wherein said disease is cancer.

28. (original) The method of claim 25, wherein said test compound comprises a cancer therapeutic.

29. (original) The method of claim 25, wherein said test compound comprises a kinase inhibitor.

30. (presently amended) A method for isolating a target population of phosphopeptides from a complex mixture of peptides, said method comprising the steps of:

(a) obtaining a proteinaceous preparation from an organism, wherein said proteinaceous preparation comprises a complex mixture of peptides comprising phosphopeptides from two or more different proteins;

(b) fractionating phosphopeptides in said proteinaceous preparation by reversed-phased chromatography to produce a fractionated proteinaceous preparation;

(c) contacting said fractionated proteinaceous preparation with at least one immobilized motif-specific, context-independent antibody that binds a motif comprising at least one phosphorylated amino acid;

(d) isolating said target ~~at least one~~ population of phosphopeptides specifically bound by

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

said immobilized antibody in step (c); and

(c) characterizing said population of phosphopeptides isolated in step (d) by mass spectrometry (MS), tandem mass spectrometry (MS-MS), and/or MS³ analysis.

31. (previously presented) The method of claim 30, further comprising the step of (f) utilizing a search program to substantially match the mass spectra obtained for at least one phosphopeptide during the characterization of step (e) with the mass spectra for a peptide of one or more known protein(s), thereby identifying the parent protein(s) of said phosphopeptide.

32. (previously presented) The method of claim 30, wherein said mass spectrometry comprises matrix-assisted laser desorption time-of-flight (MALDI-TOF) MS, wherein said tandem mass spectrometry comprises liquid chromatography (LC)-MS/MS, and wherein said MS³ analysis comprises LC-MS³.

33. (previously presented) The method of claim 30, wherein step (a) further comprises digesting said proteinaceous preparation to produce a complex mixture of peptides.

34. (original) The method of claim 30, wherein said motif-specific, context-independent antibody of step (c) comprises a general phosphotyrosine-specific antibody, a general phosphothreonine-specific antibody, or a general phosphoserine-specific antibody.

35. (original) The method of claim 30, wherein said motif-specific, context-independent antibody of step (c) is specific for a phosphorylated kinase consensus substrate motif or protein-protein binding motif.

36. (previously presented) The method of claim 35, wherein said kinase consensus substrate motif is selected from the group consisting of mitogen-activated protein kinase (MAPK) consensus substrate motifs, cyclin-dependent kinase (CDK) consensus substrate motifs, protein kinase A (PKA) consensus substrate motifs, AKT consensus substrate motifs, protein kinase C (PKC) consensus substrate motifs, phosphothreonine-X-arginine, and ATM/ATR (ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related) consensus substrate motifs, p85 PI3K binding motif, phosphothreonine-proline motif, Arg-X-Tyr/Phe-X-phosphoserine motif, phosphoserine/phosphothreonine-Phe motif, polo-like kinase (PLK) consensus substrate motifs, and DNA damage-

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

induced substrate motifs, and wherein said protein-protein binding is a 14-3-3 binding motif or a 3-phosphoinositide-dependent kinase 1 (PDK1) docking motif.

37. (previously presented) The method of claim 30, wherein said reversed-phased chromatography of step (b) comprises a C18 column.

38. (previously presented) The method of claim 30, further comprising the step of (f) quantifying said isolated phosphopeptides of step (c).

39. (previously presented) The method of claim 38, wherein step (f) comprises quantifying said isolated phosphopeptides using stable isotope labeling by amino acids in cell culture (SILAC) and/or absolute quantification of peptides (AQUA) techniques.

40. (withdrawn) An immunoaffinity isolation device for the isolation of modified peptides a complex mixture, said device comprising a support comprising at least one modification-specific antibody immobilized to a rigid, non-porous or macroporous resin.

41. (withdrawn) The device of claim 40, wherein said support is selected from the group consisting of a thin capillary column having an internal diameter of about 50 to 300 micrometers and a micropipette tip.

42. (withdrawn) The device of claim 41, wherein said modification-specific antibody comprises a motif-specific, context-independent antibody.

43. (withdrawn) The device of claim 41, wherein said column is adapted to be coupled to an electrospray source on a mass spectrometer.

44. (withdrawn) An antibody that binds ubiquitin fusion degradation protein 1 (UFD1) only when phosphorylated at serine 335, but does not substantially bind to UFD1 when not phosphorylated at this residue.

45. (withdrawn) An antibody that binds protein-tyrosine phosphatase 1c (PTN6) only when phosphorylated at serine 588, but does not substantially bind to PTN6 when not phosphorylated at this residue.

APPLICANTS: Rush *et al.*
U.S.S.N.: 10/777,893

46. (withdrawn) An antibody that binds a protein phosphorylation site listed in Column 5 of Table 5 only when phosphorylated at the phosphorylatable residue indicated in Column 5, but does not substantially bind to the phosphorylation site when not phosphorylated at the indicated residue.
47. (withdrawn) An antibody that binds a protein phosphorylation site listed in Column 5 of Table 6 only when not phosphorylated at the phosphorylatable residue indicated in Column 5, but does not substantially bind to the phosphorylation site when phosphorylated at the indicated residue.
48. (withdrawn) An antibody that binds a protein phosphorylation site listed in Column 4 of Table 7 only when not phosphorylated at the phosphorylatable residue indicated in Column 4, but does not substantially bind to the phosphorylation site when phosphorylated at the indicated residue.
49. (previously presented) The method of claim 1, wherein step (a) further comprises the step of fractionating said post-translationally modified peptides in said proteinaceous preparation by reversed-phased chromatography to produce a fractionated proteinaceous preparation prior to said contact step (b).
50. (previously presented) The method of claim 49, wherein said reversed-phased chromatography of step (a) comprises a C18 column.
51. (previously presented) The method of claim 4, further comprising the step of (f) quantifying at least one isolated post-translationally modified peptide of step (d).
52. (previously presented) The method of claim 51, wherein step (f) comprises quantifying said isolated post-translationally modified peptide using stable isotope labeling by amino acids in cell culture (SILAC) and/or absolute quantification of peptides (AQUA) techniques.
53. (previously presented) The method of claim 49, wherein said immobilized post-translational modification specific antibody comprises an antibody that binds a single modified amino acid selected from the group consisting of an acetylated amino acid, a glycosylated amino acid, and a methylated amino acid.